Can you take Chlorotrianisene with Miglitol?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- chlorotrianisene
- miglitol
Drug interactions
Moderate drug interactions
Moderate:
chlorotrianisene miglitol
Applies to: chlorotrianisene and miglitol
Chlorotrianisene may interfere with blood glucose control and reduce the effectiveness of miglitol and other diabetic medications. Monitor your blood sugar levels closely. You may need a dose adjustment of your diabetic medications during and after treatment with chlorotrianisene. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
miglitol Food/Lifestyle
Applies to: miglitol
Alcohol may affect blood glucose levels in patients with diabetes. Both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) may occur, depending on how much and how often you drink. You should avoid using alcohol if your diabetes is not well controlled or if you have high triglycerides, neuropathy (nerve damage), or pancreatitis. Moderate alcohol consumption generally does not affect blood glucose levels if your diabetes is under control. However, it may be best to limit alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with your normal meal plan. Avoid drinking alcohol on an empty stomach or following exercise, as it may increase the risk of hypoglycemia. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Minor food/lifestyle interactions
Minor:
chlorotrianisene Food/Lifestyle
Applies to: chlorotrianisene
Information for this minor interaction is available on the professional version.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Diabetic Ketoacidosis, Noninfectious Colitis, Malabsorption Syndrome, Renal Dysfunction, and Intestinal Obstruction.
Colonic Ulceration
Major:
miglitol
Miglitol has a major potential interaction with Colonic Ulceration.
The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.
Diabetic Ketoacidosis
Major:
miglitol
Miglitol has a major potential interaction with Diabetic Ketoacidosis.
The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.
Intestinal Obstruction
Major:
miglitol
Miglitol has a major potential interaction with Intestinal Obstruction.
The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.
Malabsorption Syndrome
Major:
miglitol
Miglitol has a major potential interaction with Malabsorption Syndrome.
The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.
Noninfectious Colitis
Major:
miglitol
Miglitol has a major potential interaction with Noninfectious Colitis.
The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.
Renal Dysfunction
Major:
miglitol
Miglitol has a major potential interaction with Renal Dysfunction.
Miglitol is eliminated primarily by the kidney. Plasma miglitol levels in patients with renal impairment have been shown to proportionally increase relative to the degree of renal dysfunction. However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted. Therapy with miglitol should be administered cautiously in patients with renal insufficiency. The manufacturer does not recommend its use in patients with significantly impaired renal function.
Report options
More resources
chlorotrianisene
A total of 260 drugs are known to interact with chlorotrianisene.
- Chlorotrianisene is in the drug class estrogens.
- Chlorotrianisene is used to treat Postmenopausal Symptoms.
miglitol
A total of 310 drugs are known to interact with miglitol.
- Miglitol is in the drug class alpha-glucosidase inhibitors.
- Miglitol is used to treat Type 2 Diabetes.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.